Abstract
Purpose: :
Peroxisome proliferator-activated receptor-α (PPARα) agonist fenofibrate (LIPIDIL®) has been shown to have anti-inflammatory activity and suppress the development of experimental autoimmune encepharomyelitis. In this study, we investigated the effect of PPARα agonist fenofibrate in experimental autoimmune uveoretinitis (EAU).
Methods: :
Lewis rats were immunized with retinal S antigen peptide and the severity of EAU disease was scored. The PPARα agonist fenofibrate (20mg/kg/day) was orally administered every day from day 0 postimmunization until day 14. The eyes were obtained on day 21 postimmunization and the histological score was determined using pathological findings. The expression of inflammatory cytokines including IL-6, IL-17, and VEGF was determined immunohistochemically.
Results: :
Systemically administered PPARα agonist fenofibrate suppressed the development of EAU. The clinical scores (control:fenofibrate) were 2.83±0.93:1.17±0.98 and 3.67±0.40:1.42±0.86 on day 17 and 21 postimmunization, respectively. PPARα agonist fenofibrate also decreased the histological scores and the expression of inflammatory cytokines in the retina of EAU.
Conclusions: :
These results suggest that PPARα agonist fenofibrate may modulate the development of EAU and suppress intraocular inflammation by decreasing the production of inflammatory cytokines.
Keywords: uveitis-clinical/animal model • autoimmune disease